Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian Ministry of Health
Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian Ministry of Health
复制标题
DOI：
10.1590/s1806-37132010000200012
复制
发表时间：
2010-04-01
影响因子：
2.7
通讯作者：
Dietze, Reynaldo
中科院分区：
文献类型：
--
作者：
Maciel, Ethel Leonor Noia;Guidoni, Letícia Molino;Dietze, Reynaldo
目的：确定巴西卫生部推荐的结核病治疗方案的主要不良反应。研究方法：一项前瞻性描述性研究，涉及2003年至2006年间在巴西维托里亚市Cassiano Antonio Moraes大学医院临床研究中心接受治疗的79例结核病患者。治疗方案包括异烟肼、利福平、吡嗪酰胺和乙胺丁醇4个月，然后是利福平和异烟肼2个月。在治疗期间，每周对患者进行临床评估，每月进行一次医疗访视。结果：不良反应总发生率为83.54%。关节/骨骼/肌肉受累最常见，其次是皮肤受累（分别为24.94%和22.09%）。不良反应多发生在治疗第2个月（41.59%）。无需调整治疗方案，1例患者需要合并用药以对抗不良反应。治愈率100%。结论：与巴西卫生部推荐的新治疗方案相关的不良反应的总体发生率很高，但是，这些影响都不需要改变方案，这对评估的患者是有效的。
Objective: To determine the principal adverse effects of the tuberculosis treatment regimen recommended by the Brazilian Ministry of Health. Methods: A prospective descriptive study involving 79 tuberculosis patients treated at the Clinical Research Center of the Cassiano Antonio Moraes University Hospital, in the city of Vitoria, Brazil, between 2003 and 2006 The treatment regimen consisted of isoniazid, rifampicin, pyrazinamide and ethambutol for four months, followed by rifampicin and isoniazid for two months. During the treatment period, the patients were clinically evaluated every week and had a monthly medical visit. Results: The overall incidence of adverse effects was 83.54%. Articular/bone/muscle involvement was the most common, followed by skin involvement (24.94% and 22.09%, respectively). Adverse effects were more common in the second month of treatment (41.59%). Modification of the treatment regimen was unnecessary One patient required concomitant medication to counter the adverse effects. The cure rate was 100%. Conclusions: The overall incidence of adverse effects related to the new treatment regimen recommended by the Brazilian Ministry of Health was high However, none of those effects demanded a change in the regimen, which was effective in the patients evaluated.